Predictive value of combined analysis of pro‐NPY and ERG in localized prostate cancer

Abstract

value of combined analysis of pro-NPY and ERG in localized prostate cancer. APMIS 2018; 126: 804-813 This study aimed to investigate if combined analysis of pro-Neuropeptide Y (NPY) and ERG expression in tumor tissue are associated with biochemical failure (BF), castration-based treatment, castration-resistant prostate cancer (CRPC), and prostate cancer (PCa)-specific death for men undergoing radical prostatectomy (RP) for PCa. This study included 315 patients, who underwent RP from 2002 to 2005. Both pro-NPY and ERG expression were analyzed using immunohistochemistry and were scored as low or high and negative or positive, respectively. Risk of BF, castrationbased treatment, CRPC, and PCa-specific death were analyzed with multiple cause-specific Cox regression analyses and stratified cumulative incidences using competing risk assessment. Median follow-up was 13.0 years (95% CI: 12.7-13.2). In total, 85.7% were pro-NPY high and 14.3% were pro-NPY low. The combined analyses of pro-NPY and ERG expression was not associated with risk of BF (p = 0.7), castration-based treatment (p = 0.8), CRPC (p = 0.4) or PCa-specific death (p = 0.5). In the multiple cause-specific Cox regression analysis, pro-NPY high and ERG positivity was not associated with BF (HR: 1.02; 95% CI 0.6-1.7; p = 0.94). In conclusion the combination of pro-NPY and ERG expression did not show association with risk of BF, castration-based treatment, CRPC, and PCa-specific death following RP.

5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors

“…The cohort included 552 men who underwent RP from 1998 until 2009 at the Department of Urology, Aarhus University Hospital, Aarhus, Denmark (cohort A), and 336 men who underwent RP from 2002 until 2005, at the Department of Urology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark (cohort B) (Figure 1). Production of the TMAs and collection of the clinicopathological data has previously been described in detail [15,42]. The study was approved by the Danish National Committee on Health Research Ethics (Journal no.…”

“…Freshly cut sections of each TMA block were used for IHC staining for 5hmC (1:1000 dilution; anti-5hmC 39769 Rabbit Polyclonal antibody, Active Motif, Carlsbad, CA, USA) and ERG (cohort A: anti-ERG clone EPR3864 Rabbit Monoclonal Antibody, Epitomics, Burlingame, CA, USA, and cohort B: anti-ERG clone EPR3864 Rabbit Monoclonal Antibody, Roche Ventana, Indianapolis, IL, USA), as previously described in detail [15,42]. A separate hematoxylin & eosin (HE) stained section was used for validation of the presence of cancer in each core.…”

“…Patients with a mean 5hmC score ≤1 were classified as having a low 5hmC level and patients with a mean 5hmC score >1 were classified as having a high 5hmC level. Nuclear ERG immunoreactivity in malignant prostate epithelial cells was evaluated and scored as negative if all cores were negative, and positive if any of the cores were positive [15,42]. The assessment of the biomarkers was blinded to study end-points.…”

Complexity of Neural Component of Tumor Microenvironment in Prostate Cancer

“…An in vitro study revealed that Y1 and Y2 receptors are present in the androgen-independent human PC-3 cell line and that their activation by NPY stimulates cancer cell proliferation, which suggests its impact on castration-resistant regulation of PC [83,85]. NPY and its receptors (Y1R, Y2R, Y5R) were found to be expressed in PC cells and neuronal fibers but not in the surrounding stroma [86]. Our own results (data not published) showed a higher expression of NPY, Y1R, Y2R, and Y5R in PC tissue than in matched controls of benign prostatic hyperplasia and significantly higher expression of the NPY system in areas with neuroinvasion and extraprostatic infiltration (Fig.…”

Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome

“…PCA281: Prostate cancer tissue samples were collected from 314 RP patients between 2002 and 2005 at the Department of Urology, Rigshospitalet, Copenhagen, Denmark 48 . After exclusion of 33 patients ( Supplementary Fig.…”